Table 1

Schedule of study data collection

 FFR measurement period
Screening period registrationBaselineAdenosineNicorandil
Informed consent
Baseline characteristics
Adverse event assessment
Vital signs*
Signs and symptoms
Haematological tests†
Blood biochemical test‡
ECG
Echocardiography
Chest X-ray
Coronary angiography
Concomitant drug
Pd, Pa recording
Time to hyperaemia
Fluctuation§
Plateau time
  • ○: To be performed before enrolment.

  • ●: To be performed after enrolment; preinformed consent data may also be used.

  • *Blood pressure, and pulse (respiratory rate and peripheral oxygen saturation (SpO2) as necessary).

  • †White cell count, red blood cell, haemoglobin, haematocrit, platelet count.

  • ‡Aspartate aminotransferase, alanine aminotransferase, total bilirubin, total protein, C reactive protein, potassium, creatinine, chloride, natrium, creatine kinase, blood urea nitrogen, estimated glomerular filtration rate, brain natriuretic peptide, troponin I.

  • §Fluctuation is defined as changes in FFR value more than 0.05 during hyperaemic status by continuous adenosine infusion.

  • FFR, fractional flow reserve; Pa, mean aortic pressure; Pd, mean distal coronary pressure.